These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20705397)

  • 21. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature.
    Goldin SB; Aston J; Wahi MM
    Curr Opin Oncol; 2008 Jan; 20(1):25-33. PubMed ID: 18043253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
    Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
    Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
    [No Abstract]   [Full Text] [Related]  

  • 24. Endocrine tumors of the gastrointestinal tract: systemic treatment.
    Oberg K
    Anticancer Drugs; 1994 Oct; 5(5):503-19. PubMed ID: 7858282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
    Syrigos KN; Sitara D; Georgiou E; Harrington KJ
    Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B; Sirohi B; Corrie P
    Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
    O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
    Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
    Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on gastroenteropancreatic neuroendocrine tumors.
    Cives M; Strosberg J
    Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neuroendocrine "silent" tumors of the pancreas].
    Kubyshkin VA; Buriev IM; Abdulkerimov ZA; Gurevich LE; Kochatkov AV
    Khirurgiia (Mosk); 2004; (3):4-9. PubMed ID: 15097980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
    Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
    Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
    Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
    Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
    Anlauf M
    Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuroendocrine tumors of the pancreas. Natural history and therapeutic options].
    Wiedenmann B
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Suppl):S26-30. PubMed ID: 12704290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.